Within its last year performance, VRDN fell by -30.07%, with highs and lows ranging from $30.30 to $10.93, whereas the simple moving average fell by -5.85% in the last 200 days.
On June 14, 2023, Credit Suisse started tracking Viridian Therapeutics Inc (NASDAQ: VRDN) recommending Outperform. A report published by BTIG Research on June 14, 2023, Initiated its previous ‘Buy’ rating for VRDN. RBC Capital Mkts also rated VRDN shares as ‘Outperform’, setting a target price of $44 on the company’s shares in an initiating report dated May 30, 2023. Wells Fargo Initiated an Overweight rating on April 17, 2023, and assigned a price target of $46. Stifel initiated its ‘Buy’ rating for VRDN, as published in its report on March 30, 2023. Needham’s report from December 19, 2022 suggests a price prediction of $45 for VRDN shares, giving the stock a ‘Buy’ rating. Cowen also rated the stock as ‘Outperform’.
Analysis of Viridian Therapeutics Inc (VRDN)
Further, the quarter-over-quarter decrease in sales is -31.43%, showing a negative trend in the upcoming months.
To gain a thorough understanding of Viridian Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -56.80% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 18.26, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and VRDN is recording an average volume of 981.51K. On a monthly basis, the volatility of the stock is set at 6.41%, whereas on a weekly basis, it is put at 4.99%, with a loss of -6.76% over the past seven days. Furthermore, long-term investors anticipate a median target price of $38.27, showing growth from the present price of $17.51, which can serve as yet another indication of whether VRDN is worth investing in or should be passed over.
How Do You Analyze Viridian Therapeutics Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 11.02%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 90.43% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
VRDN shares are owned by institutional investors to the tune of 90.43% at present.
